AxioMx, founded in 2012 and based in Branford, Connecticut, is a leader in recombinant antibody technologies. Its founders, Chris McLeod and Dr. Michael Weiner, are life science entrepreneurs who have previously led successful genomics, next-generation sequencing, microfluidics, bioinformatics and proteomic organizations.
AxioMx develops synthetic antibody library
AxioMx Inc.has announced the successful completion of research, funded by a National Institute of Health SBIR grant, to develop a novel library for selection of affinity reagents. Under the research, AxioMx created a highly diverse synthetic phage-display antibody library.